Published
Amirali Salmasi, MD, MSCR, Associate Professor of Urology, University of California San Diego, La Jolla, California, explores the rationale for systemic immunotherapy in non-muscle invasive bladder cancer, emphasizing its potential role in BCG-unresponsive disease. In this 18-minute presentation, Dr. Salmasi shares that studies combining BCG with systemic immunotherapy suggest only marginal improvements, raising questions about its necessity for non-invasive tumors. The experts on the forum enhance the discussion.
- Category
- Oncology
Be the first to comment
Up Next
-
08:33
The ABLE-32 Study: Nadofaragene Firadenovec for Intermediate-Risk NMIBC
-
07:24
Where We Were and Where We Are in NMIBC Trials and Therapies
-
05:50
Cretostimogene for High-Risk NMIBC: CORE-008, BOND-003, and PIVOT-006
-
08:50
The SunRISe Trials and TAR-200: Bladder-Sparing Therapies for NMIBC
-
12:02
AI-Powered Biomarkers and Precision Medicine in High-Risk NMIBC
-
04:32
Treatment Options for BCG-Unresponsive NMIBC: Balancing Efficacy, Logistics, and Patient Preferences
-
10:33
Daniel P. Petrylak - Clinical Trials in MIBC and NMIBC
-
08:22
Bladder-Sparing with Systemic Therapy: Insights from RETAIN-2 and Future Directions
-
10:29
Treating BCG-Refractory Disease and Explaining NMIBC Treatment Options to Patients
-
09:00
Lifestyle Modification in the Setting of New Prevention Therapies
-
09:07
Cardiology for Beginners: Basics of Heart Sounds and Murmurs (with examples)
-
13:45
How to Become a Cardiologist | Cardiac Electrophysiologist
-
04:14
V 00592 Cardiology Fellowship Video Dr Vranian V5
-
05:17
Cardiology Fellowship at SIU Medicine
-
04:15
Cardiology Fellowship Program at Danbury Hospital
-
05:49
Practice Question: Cardiology #1, USMLE Step 1, COMLEX Level 1
-
04:07
Dr. Muhammed Raza on advice for Fellows interested in Interventional Cardiology
-
07:36
Congenital Heart Disease – Cardiology | Lecturio
-
05:18
Cardiology Fellowship at IU School of Medicine
-
04:36
What are different types of Cardiology Tests | SPS Hospitals
